• OSE Immunotherapeutics reported first patient dosing in RENGEVITY-201, a Phase 2 kidney-transplant study of pegrizeprument (VEL-101).
• No clinical results were presented; the trial is evaluating whether the drug can help prevent organ rejection in renal transplant recipients.
• Veloxis holds global rights for transplant indications, covering development, manufacturing, and planned commercialization under a 2021 license.
• FDA granted orphan-drug status for liver-transplant rejection prevention in December 2025, then for heart-transplant rejection prophylaxis in March 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSE Immunotherapeutics SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609091200OMX_____CNEWS_FR_GNW1001261877_fr) on September 09, 2026, and is solely responsible for the information contained therein.